(Q35581131)

9 August 2017

title

Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases (English)

1 reference

9 August 2017

main subject

organ transplantation

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1517/14728214.8.1.47

31 March 2024

author name string

Pascale Burtin

2

1 reference

9 August 2017

John M. Kovarik

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14610911

31 March 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

9 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/14728214.8.1.47

1 reference

https://api.crossref.org/works/10.1517/14728214.8.1.47

Expert Opinion on Emerging Drugs

31 March 2024

language of work

1 reference

9 August 2017

volume

8

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

47-62

1 reference

Emerging drugs in psoriasis

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Regulatory T cells in transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

The T-cell repertoire available for recognition of self-antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

The two-signal model of T-cell activation after 30 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Current treatment practice in immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Strategies to improve long-term outcomes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Advances in the treatment of rheumatoid arthritis: old versus new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Immunotherapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Guidelines for the management of rheumatoid arthritis: 2002 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Cytokine inhibitors in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Therapeutic developments in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Therapy of systemic lupus erythematosus: new agents and new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Chronic rejection of renal transplants: new clinical insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Immunotherapy of multiple sclerosis: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

The role of costimulatory molecules as targets for new immunosuppressives in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Immune-adhesion molecules in the prevention of allograft rejection and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Review of the proliferation inhibitor everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

CTLA4-Ig: a novel immunosuppressive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Clinical trials of antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.8.1.47

Call for revolution: a new approach to describing allograft deterioration

21 January 2018

20

1 reference

https://api.crossref.org/works/10.1517/14728214.8.1.47

Severe Psoriasis – Oral Therapy with a New Retinoid

31 March 2024

43

1 reference

https://api.crossref.org/works/10.1517/14728214.8.1.47

A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials

31 March 2024

44

1 reference

https://api.crossref.org/works/10.1517/14728214.8.1.47

Challenges for the translation of T cell costimulatory blockade therapies to the clinic

31 March 2024

49

1 reference

https://api.crossref.org/works/10.1517/14728214.8.1.47

31 March 2024

Identifiers

1 reference

release_vpggw4wa75bedjr67wi245lg6u

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vpggw4wa75bedjr67wi245lg6u

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference